Research Accelerating Medicines Partnership® Program – Rheumatoid Arthritis, Systemic Lupus Erythematosus
Research Biomarkers Consortium – Sarcopenia as a Valid Biomarker for Identifying Individuals at Risk of Disability
Research Biomarkers Consortium – Treatments Against RA and Effect on FDG PET-CT (TARGET Biomarker Study)
Research Biomarkers Consortium - Establish Guidelines for Initial Diagnostic Criteria for “Sarcopenia with Clinically Important Weakness” and Associated Evidence for Treatment Benefit
